Table 1.
Results of clinical trial for new agents targeting co-inhibitory signals on T cells and epigenetic alterations.
| Trial name/code | Setting | Phase | Molecule | N° of NSCLC patients | ORR (CR) | DCR | Median PFS | Median OS |
|---|---|---|---|---|---|---|---|---|
| ENCORE 601 | Pretreated with ICIs | I | Entinostat (histone deacetylase inhibitor)+ pembrolizumab | 71 | 9,2% | – | 2,8 mo | 11,2 mo |
| NCT02608268 | Pretreated with ICIs | II | MBG-453 (anti-TIM3) + spartalizumab | 17 | 0/17 | 7/17 (41,2%) | – | – |
| CITYSCAPE (NCT03563716) | First line PD-L1+ | II random | Tiragolumab (anti-TIGIT) + atezo vs Placebo + atezolizumab | 135 | 37,3% vs 20,6% | – | 5,6 mo vs 3,9 mo | – |
| CTRI/2017/12/011026 | Pretreated, ICIs naïve | II | CA-170 (dual VISTA and PD-L1 oral inhibitor) 400 mg | 8 non squamous | 0/8 | 6/8 (75%) | 19,5 weeks | – |
| NCT03665285 | Pretreated with ICIs | I | NC318 (anti Siglec-15) | 13 | 2/10 (1) | 6/10 (60%) | – | – |
| NCT03667716 | Pretreated with ICIs | I | COM701 (PVRIG inhibitor) +/- Nivolumab | ? | 0 | 6/20 (3 NSCLC) | – | – |